Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China

Trial StartIBI363/TAK-928BevacizumabPositive

AI Analysis

Summary

Innovent Biologics announced the first patient dosed in a pivotal registrational study of IBI363/TAK-928, a PD-1/IL-2α-biased bispecific fusion protein combined with bevacizumab for late-line advanced colorectal cancer in China.

Clinical Trial Data

Phase

pivotal

Outcome Details

First patient dosed in pivotal registrational study

Importance:6/10

Sentiment:

0.60

oncologycolorectal cancerbispecific antibodycombination therapyChinaclinical trial

Related Companies

$TAK

Read the original article

Published by PR Newswire Biotech on August 6, 2026 12:00 AM

Read Original